Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.

Kakolyris S; Agelidou A; Androulakis NTsaroucha EKouroussis ChAgelidou MKarvounis NVeslemes MChristophylakis ChArgyraki AGeroyianni AGeorgoulias V

首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.

【24h】

Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.

机译：顺铂+依托泊苷化疗紧随其后胸辐照和紫杉醇+顺铂联合治疗的患者小细胞肺癌有限阶段。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

PURPOSE: To evaluate the efficacy and tolerance of a cisplatin plus etoposide regimen followed by thoracic radiotherapy (TRT) and paclitaxel plus cisplatin consolidation chemotherapy in patients with limited stage small cell lung cancer (SCLC). PATIENTS AND METHODS: Thirty-nine patients with limited SCLC were enrolled onto this study. Patients received three courses of cisplatin 75 mg/m2 i.v., day 1 and etoposide 100 mg/m2 i.v., days 1-3 (EP regimen), followed by TRT (45-56 Gy administered in 15 fractions), and three courses of paclitaxel 175 mg/m2 i.v., day 1 and cisplatin, as previously, on day 2 (PP regimen); cycles were repeated every 21 days. RESULTS: All patients were evaluable for toxicity and 34 for response. The overall response rate was 67% (CR: 26%; PR: 41%; intention-to-treat analysis) (95% CI: 53.0-84.2%). After a median follow-up period of 15 months, the median survival time was 15 months, the median time to tumor progression 8.3 months and the 1-year survival rate 53.8%. Grade 3/4 neutropenia occurred in 39% and 36% of patients receiving EP and PP regimens, respectively. The incidence of febrile neutropenia was 5% and 3% for EP and PP regimens, respectively. Other hematologic and non-hematologic toxicities were mild, with the exception of esophagitis occurring in 36% of patients during and/or immediately after radiotherapy. CONCLUSION: Consolidation therapy with PP after sequential EP and thoracic radiotherapy is feasible and well-tolerated; however, the efficacy results are comparable with those previously obtained in the same patients' population using a combination of EP and TRT.

机译：目的:评估的有效性和宽容顺铂+依托泊苷方案紧随其后胸部放射治疗(TRT)和紫杉醇+顺铂联合化疗的病人有限的小细胞肺癌(SCLC)阶段。患者和方法:患者39SCLC被加入到这项研究有限。患者接受顺铂75三门课程mg / m2增长值,第一天和依托泊苷100 mg / m2注射。1 - 3天(EP方案),其次是泰爱泰党(45-56 Gy管理15个分数),和三个课程紫杉醇175 mg / m2的增长值,第一天顺铂,正如前面,第二天(PP方案);周期是每21天重复。患者可评价的毒性和34响应。26%;置信区间:53.0 - -84.2%)。15个月,平均生存时间是158.3个月,中位时间肿瘤恶化个月及1年生存率53.8%。3/4嗜中性白血球减少症发生在的39%和36%病人接受EP和PP方案,分别。嗜中性白血球减少症是EP和PP方案,5%和3%分别。non-hematologic毒性轻微,异常的食管炎发生在36%的病人期间和/或后立即放射治疗。后页顺序EP和胸放射治疗是可行的,同时;然而,疗效结果具有可比性那些之前获得在同一病人的人口使用EP的组合,泰爱泰党。

著录项

来源
《Lung cancer: Journal of the International Association for the Study of Lung Cancer》 |2006年第1期|59-65|共7页
作者
Kakolyris S; Agelidou A; Androulakis NTsaroucha EKouroussis ChAgelidou MKarvounis NVeslemes MChristophylakis ChArgyraki AGeroyianni AGeorgoulias V;
展开▼
作者单位

Department of Medical Oncology, University General Hospital of Alexandroupolis, Alexandroupolis, Greece.;

reventionsource.bc.ca;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类肿瘤学;
关键词
Cisplatin; Paclitaxel; Etoposidelimited stage small cell lung cancerTumor ProgressionPatientsEtoposide-Platinol Regimen;

机译：小顺铂、紫杉醇、Etoposidelimited阶段细胞肺癌cancerTumorProgressionPatientsEtoposide-Platinol养生法;

相似文献

外文文献
中文文献

1. Influence of tumor response on the survival of patients with extensive-stage small-cell lung cancer treated with the etoposide plus cisplatin chemotherapy regimen [J] . Guojing Zhang, Yaling Han, Xiaodong Xie, 中德临床肿瘤学杂志（英文版） . 2015,第002期
2. Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide- carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer： a retrospective analysis of 62 cases [J] . Yue-Ya Li, Chan Zhou, Deng-Xia Yang, 癌症生物学与医学：英文版 . 2015,第002期
3. Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase Ⅱ open-label clinical study [J] . Shanshan Qin, Jie Qiao, Yu Feng, 中国癌症研究（英文版） . 2019,第002期
4. Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma [J] . Liangze Zhang, Weiwei Li, Xiao Lyu, 中国癌症研究（英文版） . 2017,第002期
5. Adu; Aged;; Aged, 80 and over;; Antineoplastic Agents;; Carcinoma, Non-Small-Cell Lung;; Cisplatin;; Cohort Studies;; Deoxycytidine;; Female;; Humans;; Lung Neoplasms;; Male;; Middle Aged;; Mitomycin;; Neoadjuvant Therapy;; Neoplasm Staging;; Pneumonectomy;; Retrospective Studies;; Treatment Outcome;; Vinblastine;; *成年人;; 老年人;; 老年人, 80以上;; 抗肿瘤药;; 癌, 非小细胞肺;; 顺铂;; 队列研究;; 脱氧胞苷;; 肺肿瘤;; 肿瘤辅助疗法;; 肿瘤分期;; 肺切除术;; 回顾性研究;; 治疗结果;; 长春碱 [J] . Clinical cancer research: an official journal of the American Association for Cancer Research . 2009,第18期

机译：Adu; Aged;; Aged, 80 and over;; Antineoplastic Agents;; Carcinoma, Non-Small-Cell Lung;; Cisplatin;; Cohort Studies;; Deoxycytidine;; Female;; Humans;; Lung Neoplasms;; Male;; Middle Aged;; Mitomycin;; Neoadjuvant Therapy;; Neoplasm Staging;; Pneumonectomy;; Retrospective Studies;; Treatment Outcome;; Vinblastine;; *成年人;; 老年人;; 老年人, 80以上;; 抗肿瘤药;; 癌, 非小细胞肺;; 顺铂;; 队列研究;; 脱氧胞苷;; 肺肿瘤;; 肿瘤辅助疗法;; 肿瘤分期;; 肺切除术;; 回顾性研究;; 治疗结果;; 长春碱
6. Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes [O] . Oyama, Katsunobu, Fushida, Sachio, Kinoshita, Jun, 2012

机译：Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and s-1 (DCs therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes

Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.

摘要

著录项

相似文献

相关主题

期刊订阅